Skip to main content

Advertisement

Log in

Basal 18 F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography as a prognostic biomarker in patients with locally advanced breast cancer

European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Aim

To explore the relationship between basal 18 F-FDG PET/CT information in breast tumours and survival in locally advanced breast cancer (LABC).

Methods

This prospective, multicentre study included 198 women diagnosed with LABC. All patients underwent 18 F-FDG PET/CT prior to treatment. The maximum standardized uptake value (SUVmax) in tumor (T), lymph nodes (N) and the N/T ratio was obtained in all cases. Stage according to PET/CT imaging (metabolic stage) and conventional imaging techniques (clinical stage) was established. During follow-up, patient status was established (disease free status or not). The relationship between all the variables and overall survival (OS) and disease-free survival (DFS) was analysed using the Kaplan-Meier and Cox regression methods. A ROC analysis was performed to obtain a cut-off value of SUVmax that was useful in the prediction of outcome.

Results

The mean SUVmax ± SD values in the primary tumour, lymph nodes and the SUVmax N/T index were 7.40 ± 5.57, 4.17 ± 4.74 and 0.73 ± 1.20, respectively. Higher semiquantitative metabolic values were found in more advanced metabolic and clinical stages. During follow-up, 78.4 % of patients were free of disease. Significant relationships were observed between SUVT and SUVN and patient status. With respect to OS and DFS, significant differences were detected for the metabolic stage. Kaplan-Meier analysis revealed that using the cut-off values, a primary-tumour SUVmax ≥ 6.05 or a nodal SUVmax ≥2.25 were significantly correlated with DFS and OS.

Conclusion

PET imaging with 18 F-FDG offers prognostic information for LABC that can be obtained preoperatively and noninvasively

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992;22:207–19.

    Article  CAS  PubMed  Google Scholar 

  2. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. Cancer. 1993;72:2979–85.

    Article  CAS  PubMed  Google Scholar 

  3. Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/ computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008;38:250–8.

    Article  PubMed  Google Scholar 

  4. García Vicente AM, Soriano Castrejón A, Relea Calatayud F, Palomar Muñoz A, León Martín AA, Chacón López-Muñiz I, et al. 18F-FDG retention index and biologic prognostic parameters in breast cancer. Clin Nucl Med. 2012;37:460–6.

    Article  PubMed  Google Scholar 

  5. Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 2008;26:4449–57.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer. 1998;82:2227–34.

    Article  CAS  PubMed  Google Scholar 

  7. Inoue T, Yutani K, Taguchi T, Tamaki Y, Shiba E, Noguchi S. Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography. J Cancer Res Clin Oncol. 2004;130:273–8.

    Article  PubMed  Google Scholar 

  8. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, et al. Comparison of Triple-negative and Estrogen Receptor positive/ Progesterone Receptor positive/HER2-negative Breast Carcinoma Using Quantitative Fluorine-18 Fluorodeoxyglucose/Positron Emission Tomography Imaging Parameters. A Potentially Useful Method for Disease Characterization. Cancer. 2008;112:995–1000.

    Article  CAS  PubMed  Google Scholar 

  10. Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M. The Relationship between FDG Uptake in PET Scans and Biological Behavior in Breast Cancer. Breast Cancer. 2007;14:260–8.

    Article  PubMed  Google Scholar 

  11. Song B-I, Hong C, Lee H, Kang S, Jeong SY, Kim HW, et al. Prognostic value of primary tumor uptake on F-18 FDG PET/CT in patients with invasive ductal breast cancer. Nucl Med Mol Imaging. 2011;45:117–24.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. O JH, Choi WH, Han EJ, Choi E-K, Chae BJ, Park Y-G, et al. The prognostic value of 18F-FDG PET/CT for early recurrence in operable breast cancer: comparison with TNM Stage. Nucl Med Mol Imaging. 2013;47:263–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Groheux D, Giacchetti S, Delord M, de Roquancourt A, Merlet P, Hamy AS, et al. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2015;42:377–85.

    Article  CAS  PubMed  Google Scholar 

  14. Hyun CL, Lee HE, Kim KS, Kim SW, Kim JH, Choe G, et al. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol. 2008;61:317–21.

    Article  CAS  PubMed  Google Scholar 

  15. Song B-I, Lee S-W, Jeong SY, Chae YS, Lee WK, Ahn B-C, et al. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer. J Nucl Med. 2012;53:1337–44.

    Article  CAS  PubMed  Google Scholar 

  16. Chang C-C, Tu H-P, Chen Y-W, Lin C-Y, Hou M-F. Tumour and lymph node uptakes on dual-phased 2-deoxy-2-[18F]fluoro-D-glucose parameters in breast cancer positron emission tomography/computed tomography correlate with prognostic. J Inter Med Res. 2014;42:1209–21.

    Article  Google Scholar 

  17. Lee AY, Choi SJ, Jung KP, Park JS, Lee SM, Bae SK. Characteristics of Metastatic Mediastinal Lymph Nodes of Non-Small Cell Lung Cancer on Preoperative F-18 FDG PET/CT. Nucl Med Mol Imaging. 2014;48:41–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Koksal D, Demirag F, Bayiz H, Ozmen O, Tatci E, Berktas B, et al. The correlation of SUVmax with pathological characteristics of primary tumor and the value of Tumor/ Lymph node SUVmax ratio for predicting metastasis to lymph nodes in resected NSCLC patients. J Cardiothorac Surg. 2013;8:63.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Cerfolio RJ, Bryant AS. Ratio of the maximum standardized uptake value on FDG-PET of the mediastinal (N2) lymph nodes to the primary tumor may be a universal predictor of nodal malignancy in patients with non-small cell lung cancer. Ann Thorac Surg. 2007;83:1826–30.

    Article  PubMed  Google Scholar 

  20. Humbert O, Berriolo-Riedinger A, Cochet A, Gauthier M, Charon-Barra C, Guiu S, et al. Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using 18F-FDG PET in luminal HER2-negative breast cancer. Eur J Nucl Med Mol Imaging. 2014;41:416–27.

    Article  CAS  PubMed  Google Scholar 

  21. Aogi K, Kadoya T, Sugawara Y, Kiyoto S, Shigematsu H, Masumoto N, et al. Utility of 18F FDG-PET/CT for predicting prognosis of luminal-type breast cancer. Breast Cancer Res Treat. 2015;150:209–17.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Riedl CC, Slobod E, Jochelson M, Morrow M, Goldman DA, Gonen M, et al. Retrospective Analysis of 18F-FDG PET/CT for Staging Asymptomatic Breast Cancer Patients Younger Than 40 Years. J Nucl Med. 2014;55:1578–83.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Cochet A, Dygai-Cochet I, Riedinger JM, Humbert O, Berriolo- Riedinger A, Toubeau M, et al. (18)F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations. Eur J Nucl Med Mol Imaging. 2014;41:428–37.

    Article  PubMed  Google Scholar 

  24. Groheux D, Hindié E, Delord M, Giacchetti S, Hamy AS, de Bazelaire C, et al. Prognostic impact of 18FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst. 2012;104:1879–87.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Kim JY, Lee SH, Kim S, Kang T, Bae JT. Tumour 18 F-FDG uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes. Eur Radiol. 2015;25:1172–81.

    Article  PubMed  Google Scholar 

  26. Ferguson NL, Bell J, Heidel R, Lee S, Vanmeter S, Duncan L, et al. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women. Breast J. 2013;19:22–30.

    Article  PubMed  Google Scholar 

  27. Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999;17:2334–40.

    CAS  PubMed  Google Scholar 

  28. García Vicente AM, Soriano Castrejón A, Cruz Mora MA, González Ageitos A, Muñoz Sánchez Mdel M, León Martín A, et al. Semiquantitative lymph node assessment of 18F-FDG PET/CT in locally advanced breast cancer: correlation with biological prognostic factors. Eur J Nucl Med Mol Imaging. 2013;40:72–9.

    Article  PubMed  Google Scholar 

Download references

No disclaimer

All the authors have participated in the writing and revision of this article and take public responsibility for its content.

Conflict of Interest

The authors declare that they have no conflicts of interest.

Research involving Human Participants and/or Animals

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ana María García Vicente.

Additional information

The present publication was approved by all the authors and by the responsible authorities where the work was carried out.

All the authors confirm that the article is not under consideration for publication elsewhere.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

García Vicente, A.M., Soriano Castrejón, Á., López-Fidalgo, J.F. et al. Basal 18 F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography as a prognostic biomarker in patients with locally advanced breast cancer. Eur J Nucl Med Mol Imaging 42, 1804–1813 (2015). https://doi.org/10.1007/s00259-015-3102-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-015-3102-x

Keywords

Navigation